Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival

被引：34

作者：

van Besien, Koen ^{[1
,2
]}

Hari, Parameswaran ^{[3
]}

Zhang, Mei-Jie ^{[3
]}

Liu, Hong-Tao ^{[4
]}

Stock, Wendy ^{[4
]}

Godley, Lucy ^{[4
]}

Odenike, Olatoyosi ^{[4
]}

Larson, Richard ^{[4
]}

Bishop, Michael ^{[4
]}

Wickrema, Amittha ^{[4
]}

Gergis, Usama ^{[1
,2
]}

Mayer, Sebastian ^{[1
,2
]}

Shore, Tsiporah ^{[1
,2
]}

Tsai, Stephanie ^{[1
,2
]}

Rhodes, Joanna ^{[1
,2
]}

Cushing, Melissa M. ^{[5
]}

Korman, Sandra ^{[3
]}

Artz, Andrew ^{[1
,2
]}

机构：

[1] Weill Cornell Med Coll, Dept Hematol Oncol, New York, NY 10065 USA

[2] Weill Cornell Med Coll, Stem Cell Transplant Program, Meyer Canc Ctr, New York, NY 10065 USA

[3] Med Coll Wisconsin, Ctr Int Bone Marrow Transplant Res, Milwaukee, WI 53226 USA

[4] Univ Chicago, Sect Hematol Oncol, Hematopoiet Cellular Therapy Program, Chicago, IL 60637 USA

[5] Weill Cornell Med Coll, Cellular Therapy Lab, Dept Pathol, New York, NY USA

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 05期

关键词：

HEMATOPOIETIC-CELL TRANSPLANTATION; ALTERNATIVE DONOR TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; BLOOD TRANSPLANTATION; ANTITHYMOCYTE GLOBULIN; UNRELATED DONOR; BONE-MARROW; MYELODYSPLASTIC SYNDROME; 3RD-PARTY DONOR; OLDER PATIENTS;

D O I：

10.3324/haematol.2015.138594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Umbilical cord blood stem cell transplants are commonly used in adults lacking HLA-identical donors. Delays in hematopoietic recovery contribute to mortality and morbidity. To hasten recovery, we used co-infusion of progenitor cells from a partially matched related donor and from an umbilical cord blood graft (haplo-cord transplant). Here we compared the outcomes of haplo-cord and double-cord transplants. A total of 97 adults underwent reduced intensity conditioning followed by haplo-cord transplant and 193 patients received reduced intensity conditioning followed by double umbilical cord blood transplantation. Patients in the haplo-cord group were more often from minority groups and had more advanced malignancy. Haplo-cord recipients received fludarabine-melphalan-anti-thymocyte globulin. Double umbilical cord blood recipients received fludarabine-cyclophosphamide and low-dose total body irradiation. In a multivariate analysis, haplo-cord had faster neutrophil (HR=1.42, P=0.007) and platelet (HR=2.54, P<0.0001) recovery, lower risk of grade II-IV acute graft-versus-host disease (HR=0.26, P<0.0001) and chronic graft-versus-host disease (HR=0.06, P<0.0001). Haplo-cord was associated with decreased risk of relapse (HR 0.48, P=0.001). Graft-versus-host disease-free, relapse-free survival was superior with haplo-cord (HR 0.63, P=0.002) but not overall survival (HR=0.97, P=0.85). Haplo-cord transplantation using fludarabine-melphalan-thymoglobulin conditioning hastens hematopoietic recovery with a lower risk of relapse relative to double umbilical cord blood transplantation using the commonly used fludarabine-cyclophosphamide-low-dose total body irradiation conditioning. Graft-versus-host disease-free and relapse-free survival is significantly improved. Haplo-cord is a readily available graft source that improves outcomes and access to transplant for those lacking HLA-matched donors.

引用

页码：634 / 643

页数：10

共 50 条

[1] Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders
Kawaguchi, Koji
Umeda, Katsutsugu
Miyamoto, Satoshi
Yoshida, Nao
Yabe, Hiromasa
Koike, Takashi
Kajiwara, Michiko
Kawaguchi, Hiroshi
Takahashi, Yoshiyuki
Ishimura, Masataka
Sakaguchi, Hirotoshi
Hama, Asahito
Cho, Yuko
Sato, Maho
Kato, Keisuke
Sato, Atsushi
Kato, Koji
Tabuchi, Ken
Atsuta, Yoshiko
Imai, Kohsuke
BONE MARROW TRANSPLANTATION, 2023, 58 (05) : 600 - 602
[2] Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders
Koji Kawaguchi
Katsutsugu Umeda
Satoshi Miyamoto
Nao Yoshida
Hiromasa Yabe
Takashi Koike
Michiko Kajiwara
Hiroshi Kawaguchi
Yoshiyuki Takahashi
Masataka Ishimura
Hirotoshi Sakaguchi
Asahito Hama
Yuko Cho
Maho Sato
Keisuke Kato
Atsushi Sato
Koji Kato
Ken Tabuchi
Yoshiko Atsuta
Kohsuke Imai
Bone Marrow Transplantation, 2023, 58 : 600 - 602
[3] Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant
Solomon, Scott R.
Sizemore, Connie
Zhang, Xu
Ridgeway, Michelle
Solh, Melhem
Morris, Lawrence E.
Holland, H. Kent
Bashey, Asad
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (07) : 1208 - 1214
[4] Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) after Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Older Patients with Myeloid Malignancies
Nazha, Aziz
Rybicki, Lisa
Abounader, Donna
Bolwell, Brian
Dean, Robert M.
Ferraro, Christina
Gerds, Aaron
Jagadeesh, Deepa
Hamilton, Betty Ky
Hill, Brian T.
Kalaycio, Matt E.
Liu, Hein
Pohlman, Brad
Sobecks, Ronald M.
Starn, Jamie
Winslow, Victoria
Sekeres, Mikkael
Majhail, Navneet S.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S205 - S206
[5] Graft-versus-Host Disease-Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders
Salas, Maria Queralt
Kumar, Rajat
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (02) : 428 - 428
[6] Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults
Mehta, Rohtesh S.
de Latour, Regis Peffault
DeFor, Todd E.
Robin, Marie
Lazaryan, Aleksandr
Xhaard, Alienor
Bejanyan, Nelli
de Fontbrune, Flore Sicre
Arora, Mukta
Brunstein, Claudio G.
Blazar, Bruce R.
Weisdorf, Daniel J.
MacMillan, Margaret L.
Socie, Gerard
Holtan, Shernan G.
HAEMATOLOGICA, 2016, 101 (06) : 764 - 772
[7] Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups
Inamoto, Yoshihiro
Kimura, Fumihiko
Kanda, Junya
Sugita, Junichi
Ikegame, Kazuhiro
Nakasone, Hideki
Nannya, Yasuhito
Uchida, Naoyuki
Fukuda, Takahiro
Yoshioka, Kosuke
Ozawa, Yukiyasu
Kawano, Ichiro
Atsuta, Yoshiko
Kato, Koji
Ichinohe, Tatsuo
Inoue, Masami
Teshima, Takanori
HAEMATOLOGICA, 2016, 101 (12) : 1592 - 1602
[8] Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation
Holtan, Shernan G.
Zhang, Lin
Defor, Todd E.
Bejanyan, Nelli
Arora, Mukta
Rashidi, Armin
Lazaryan, Aleksandr
Kotiso, Florence
Blazar, Bruce R.
Wagner, John E.
Brunstein, Claudio G.
MacMillan, Margaret L.
Weisdorf, Daniel J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1884 - 1889
[9] Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success
Kawamura, Koji
Nakasone, Hideki
Kurosawa, Saiko
Yoshimura, Kazuki
Misaki, Yukiko
Gomyo, Ayumi
Hayakawa, Jin
Tamaki, Masaharu
Akahoshi, Yu
Kusuda, Machiko
Kameda, Kazuaki
Wada, Hidenori
Ishihara, Yuko
Sato, Miki
Terasako-Saito, Kiriko
Kikuchi, Misato
Kimura, Shun-ichi
Tanihara, Aki
Kako, Shinichi
Kanamori, Heiwa
Mori, Takehiko
Takahashi, Satoshi
Taniguchi, Shuichi
Atsuta, Yoshiko
Kanda, Yoshinobu
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1521 - 1526
[10] Improved Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) Associated with Bone Marrow as the Stem Cell Source in Adults
Mehta, Rohtesh S.
deLatour, Regis Peffault
Defor, Todd E.
Robin, Marie
Lazaryan, Aleksandr
Xhaard, Alienor
Bejanyan, Nelli
de Fontbrune, Flore Sicre
Arora, Mukta
Brunstein, Claudio G.
Blazar, Bruce R.
Weisdorf, Daniel J.
MacMillan, Margaret L.
Socie, Gerard
Holtan, Shernan
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S49 - S49

← 1 2 3 4 5 →